Pasquale Morese
Ayaz Ahmad
Dr Mathew Martin
Dr Richard Noble
Sara Pintar
et al. | Correction to: Factors affecting irreversible inhibition of EGFR and influence of chirality on covalent binding (Communications Chemistry, (2025), 8, 1, (111), 10.1038/s42004-025-01501-6) | 2025 |
|
Pasquale Morese
Ayaz Ahmad
Dr Mathew Martin
Dr Richard Noble
Sara Pintar
et al. | Factors affecting irreversible inhibition of EGFR and influence of chirality on covalent binding | 2025 |
|
Dr Nicola Johnson
Dr Johanne Bentley
Lan Wang
Professor Craig Robson
Professor Nicola Curtin
| Editorial Expression of Concern: Pre-clinical evaluation of cyclin-dependent kinase 2 and 1 inhibition in anti-estrogen-sensitive and resistant breast cancer cells (British Journal of Cancer, (2010), 102, 2, (342-350), 10.1038/sj.bjc.6605479) | 2024 |
|
Dr Hannah Stewart
Dr Mathew Martin
Lan Wang
Dr Eilidh Mackenzie
Professor Mike Waring
| Conformational study into alkyl-aryl ureas to inform drug discovery | 2023 |
|
Duncan Miller
Tristan Reuillon
Dr Lauren Molyneux
Dr Tim Blackburn
Dr Noel Edwards
et al. | Parallel Optimization of Potency and Pharmacokinetics Leading to the Discovery of a Pyrrole Carboxamide ERK5 Kinase Domain Inhibitor | 2022 |
|
Islam Al-Khawaldeh
Dr Christine Basmadjian
Dr Cinzia Bordoni
Dr Suzannah Harnor
Amy Heptinstall
et al. | An alkynylpyrimidine-based covalent inhibitor that targets a unique cysteine in NF-κB-inducing kinase (NIK) | 2021 |
|
Lan Wang
Professor Nilanjan Chakraborty
| Effects of the cold wall boundary on the flame structure and flame speed in premixed turbulent combustion | 2021 |
|
Daniel Wood
Svitlana Korolchuk
Dr Natalie Tatum
Lan Wang
Professor Jane Endicott
et al. | Differences in the conformational energy landscape of CDK1 and CDK2 suggest a mechanism for achieving selective CDK inhibition | 2019 |
|
Stephanie Myers
Duncan Miller
Dr Lauren Molyneux
Dr Mercedeh Arasta
Dr Ruth Bawn
et al. | Identification of a novel orally bioavailable ERK5 inhibitor with selectivity over p38α and BRD4 | 2019 |
|
Christopher Coxon
Dr Suzannah Harnor
Dr Mathew Martin
Dr Benoit Carbain
Emeritus Professor Bernard Golding
et al. | Cyclin-Dependent Kinase (CDK) Inhibitors; Structure-Activity Relationships and Insights into the CDK-2 Selectivity of 6-Substituted 2-Arylaminopurines | 2017 |
|
Dr Christopher Wong
Dr Ian Hardcastle
Christopher Matheson
Emeritus Professor Herbie Newell
Dr Mangaleswaran Sivaprakasam
et al. | Structure-guided design of purine-based probes for selective Nek2 inhibition | 2017 |
|
Dr Gary Beale
Dr Emma Haagensen
Huw Thomas
Lan Wang
Charlotte Revill
et al. | Combined PI3K and CDK2 inhibition induces cell death and enhances in vivo anti-tumour activity in colorectal cancer | 2016 |
|
Lan Wang
Emeritus Professor Herbie Newell
Professor Steve Wedge
| Tumor cells with KRAS or BRAF mutations or ERK5/MAPK7 amplification are not addicted to ERK5 activity for cell proliferation | 2016 |
|
Dr Benoit Carbain
Dr Allyson Campbell
Dr Celine Cano
Professor Jane Endicott
Emeritus Professor Bernard Golding
et al. | 8-Substituted O-6-Cyclohexylmethylguanine CDK2 Inhibitors: Using Structure-Based Inhibitor Design to Optimize an Alternative Binding Mode | 2014 |
|
Honorine Lebraud
Emeritus Professor Bernard Golding
Elisa Meschini
Dr Celine Cano
Lan Wang
et al. | Anticancer agents targeted against cyclin-dependent kinase 2 (CDK2): Structure-based design of irreversible and reversible inhibitors | 2014 |
|
